

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	April 4, 2001
				First Named Inventor	Ginette Serrero
				Group Art Unit	1642
				Examiner Name	M. Wells
Sheet	1	of	5	Attorney Docket Number	A7542.0000/P001-E

1046 U.S. PTO  
 09/824647  
 04/04/01

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
<i>my</i>	*A	5,416,192		Shoyab, et al	5/16/95	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

Examiner Signature	<i>[Signature]</i>	Date Considered	7-7-03
--------------------	--------------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002.OMB 0651-0031  
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO			<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	Not Yet Assigned
			Filing Date	April 4, 2001
			First Named Inventor	Ginette Serrero
			Group Art Unit	1642
			Examiner Name	M. Wells
			Attorney Docket Number	A7542.0000/P001-E
Sheet	2	of	5	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Exami ner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
msj	*B	<u>Effect of Testosterone on the Growth Properties and on Epidermal Growth Factor Receptor Expression in the Teratoma-derived Tumorigenic Cell Line 1246-3A</u> , Serrero, G. et al., Cancer Research 52, 1992, pps. 4242-4247.	
	*C	<u>Molecular Biology of the Cell</u> , Alberts, B., et al., Garland Publishing, Inc., 1983.	
	*D	<u>Growth Factors in Development, Transformation, and Tumorigenesis</u> , Cross, M. et al., Cell, Vol. 64, 1991, pps. 271-280.	
	*E	<u>Autocrine Secretion and Malignant Transformation of Cells</u> , Sporn, M.B. et al., The New England Journal of Medicine, Vol. 303, 1980, pps. 878-880.	
	*F	<u>Purification of an Autocrine Growth Factor Homologous with Mouse Epithelin Precursor from a Highly Tumorigenic Cell Line</u> , Zhou, J. et al., The Journal of Biological Chemistry, Vol. 268, No. 15, 1993, pps. 10863-10869.	
	*G	<u>The Epithelin Precursor Encodes Two Proteins with Opposing Activities on Epithelial Cell Growth</u> , Plowman, G. et al., The Journal of Biological Chemistry, Vol. 267, No. 18, 1992, pps. 13073-13078.	
	*H	<u>Granulins, a Novel Class of Peptide from Leukocytes</u> , Bateman, A. et al., Biochemical and Biophysical Research Communications, Vol. 173, No. 3, 1990, pps. 1161-1168.	
	*I	<u>A Synthetic Fragment of Rat Transforming Growth Factor with Receptor Binding and Antigenic Properties</u> , Nestor, J. et al., Biochemical and Biophysical Research Communications, Vol. 129, No. 1, 1985, pps. 226-232.	
	*J	<u>In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone</u> , Adelman, J. et al., DNA, Vol. 2, No. 3, 1983, pps. 183-193.	
	*K	<u>An In Vitro Model to Study Adipose Differentiation in Serum-Free Medium</u> , Serrero, G. et al., Analytical Biochemistry 120, 1982, pps. 351-359.	
	*L	<u>Study of a Teratoma-Derived Adipogenic Cell Line 1246 and Isolation of an Insulin-Independent Variant in Serum-Free Medium</u> , Serrero-Dave, G., Cancer Center, University of California, pps. 366-376.	
	*M	<u>Tumorigenicity Associated with Loss of Differentiation and of Response to Insulin in the Adipogenic Cell Line 1246</u> , Serrero, G., In Vitro Cellular & Developmental Biology, Vol. 21, No. 9, 1985, pps. 537-540.	
	*N	<u>Decreased Transforming Growth Factor-β Response and Binding in Insulin-independent Teratoma-Derived Cell Lines with Increased Tumorigenic Properties</u> , Serrero, G. et al., Journal of Cellular Physiology, 149, 1991, pps 503-511.	
	*O	<u>Growth Inhibition of Human Breast Cancer Cells in Vitro with an Antibody against the Type I Somatomedin Receptor</u> , Arteaga, C. et al., Cancer Research 49, 1989, pps.6237-6241.	
	*P	<u>The Biological Effects of a High Molecular Weight Form of IGF II in a Pluripotential Human Teratocarcinoma Cell Line</u> , Schofield, P. et al., Anticancer Research 14, 1994, pps. 533-538.	
✓	*Q	<u>Gene therapy of murine teratocarcinoma: Separate functions for insulin-like growth factors I and II in immunogenicity and differentiation</u> , Trojan, J. et al., Proc. Natl.	

*msj y 7-7-03*

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>C mplete if Kn wn</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	April 4, 2001
				First Named Inventor	Ginette Serrero
				Group Art Unit	1642
				Examiner Name	M. Wells
Sheet	3	of	5	Attorney Docket Number	A7542.0000/P001-E

		Acad. Sci. USA, Vol. 91, 1994, pps. 6088-6092.	
my	*R	<u>Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA</u> , Trojan, J. et al., Science, Vol. 259, 1993, pps. 94-96.	
	*S	<u>Continuous cultures of fused cells secreting antibody of predefined specificity</u> , Kohler, G. et al., Nature, Vol. 256, 1975, pps. 495-497.	
	*T	<u>Production of Monoclonal Antibodies: Strategy and Tactics</u> , de St. Groth, S.F. et al., Journal of Immunology Methods, 35, 1980, pps. 1-21.	
	*U	<u>Hybridoma Techniques</u> , Schreier, M. et al., Cold Spring Harbor Laboratory, 1980.	
	*V	<u>Generation of antibody activity from immunoglobulin polypeptide chains produced in <i>Escherichia coli</i></u> , Cabilly, S. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 1984, pps. 3273-3277.	
	*W	<u>Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains</u> , Morrison, S. et al., Proc. Natl. Acad. Sci. USA, Vol. 81, 1984, pps. 6851-6855.	
	*X	<u>Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells</u> , Liu, A. et al., Proc. Natl. Acad. Sci. USA, Vol. 84, 1987, pps. 3439-3443.	
	*Y	<u><i>Escherichia coli</i> Secretion of an Active Chimeric Antibody Fragment</u> , Better, M. et al., Science, Vol. 240, 1988, pps. 1041-1043.	
	*Z	<u>Reshaping human antibodies for therapy</u> , Riechmann, L. et al., Nature, Vol. 332, 1988, pps. 323-327.	
	*AA	<u>Antibody Humanization Using Monovalent Phage Display</u> , Baca, M. et al., J. Biol. Chem., Vol. 272, No. 16, 1997, pps. 10678-10684.	
	*AB	<u>A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab</u> , Rosok, M.J. et al., J. Biol. Chem., Vol. 271, No. 37, 1996, pps. 22611-22618.	
	*AC	<u>Improved Radioimaging and Tumor Localization with Monoclonal F(ab')</u> , Wahl, R.L. et al., The Journal of Nuclear Medicine, Vol. 24, No. 4, 1983, pps. 316-325.	
	*AD	<u>Clinical Use of a Monoclonal Antibody to Bombesin-like Peptide in Patients with Lung Cancer</u> , Mulshine, J.L., Annals New York Academy of Sciences, pps. 360-372.	
	*AE	<u>Antisense RNA inhibits splicing of pre-mRNA <i>in vitro</i></u> , Munroe, S.H., The EMBO Journal, Vol. 7, No. 8, 1988, pps. 2523-2532.	
	*AF	<u>Specific Synthesis of DNA <i>in Vitro</i> via a Polymerase-Catalyzed Chain Reaction</u> , Mulis, K.B. et al., Methods in Enzymology, Vol. 155, 1987, pps. 335-350.	
	*AG	<u>Antisense approaches to cancer gene therapy</u> , Mercola, D. et al., Cancer Gene Therapy, Vol. 2, No. 1, 1995, pps 47-59.	
	*AH	<u>Gene inhibition using antisense oligodeoxynucleotides</u> , Wagner, R. W., Nature, Vol. 372, 1994, pps. 333-335.	
	*AI	<u>Molecular Cloning: A Laboratory Manual</u> , Maniatis, T. et al., Cold Spring Harbor Laboratory, 1982.	
	*AJ	<u>Design and Application of Antisense Oligonucleotides in Cell Culture, <i>in Vivo</i>, and as Therapeutic Agents</u> , Brysch, W. et al., Cellular and Molecular Neurobiology, Vol. 14, No. 5, 1994, pps. 557-568.	
	*AK	<u>Rational Design of Sequence-specific Oncogene Inhibitors Based on Antisense and Antigene Oligonucleotides</u> , Helene, C., Eur. J. Cancer, Vol. 27, No. 11, 1991, pps. 1466-1471.	
	*AL	<u>Optimization of Antisense Oligodeoxynucleotide Structure for Targeting <i>ber-abl</i>*</u>	

*my* 2 7-7-03

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	Not Yet Assigned
				Filing Date	April 4, 2001
				First Named Inventor	Ginette Serrero
				Group Art Unit	1642
				Examiner Name	M. Wells
Sheet	4	of	5	Attorney Docket Number	A7542.0000/P001-E

		mRNA, Giles, R.V. et al., Blood, Vol. 86, No. 2, 1995, pps. 744-754.	
my	*AM	<u>Extending the chemistry that supports genetic information transfer <i>in vivo</i>: Phosphorothioate DNA, phosphorothioate RNA, 2'-O-methyl RNA, and methylphosphonate DNA</u> , Thaler, D.S. et al., Proc. Natl. Acad. Sci. USA, Vol. 93, 1996, pps. 1352-1356	
	*AN	<u>Oligonucleotide N3'-P5' phosphoramidates as antisense agents</u> , Gryaznov, S. et al., Nucleic Acids Research, Vol. 24, No. 8, 1996, pps. 1508-1514.	
	*AO	<u>Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells</u> , Lappalainen, K. et al., Biochimica et Biophysica Acta 1196, 1994, pps. 201-208.	
	*AP	<u>Block of AIDS-Kaposi's Sarcoma (KS) Cell Growth, Angiogenesis, and Lesion Formation in Nude Mice by Antisense Oligonucleotide Targeting Basic Fibroblast Growth Factor</u> , Ensoli, B. et al., The Journal of Clinical Investigation, Inc., Vol. 94, 1994, pps. 1736-1746.	
	*AQ	<u>Growth Inhibition of Malignant CD5+B (B-1) Cells by Antisense IL-10 Oligonucleotide</u> , Peng, B. et al., Leukemia Research, Vol. 19, No. 3, 1995, pps. 159-167.	
	*AR	<u>Review: Optimizing inducer and culture conditions for expression of foreign proteins under the control of the lac promoter</u> , Donovan, R.S. et al., Journal of Industrial Microbiology, 16, 1996, pps. 145-154.	
	*AS	<u>Prokaryotic gene expression <i>in vitro</i>: Transcription-translation coupled systems</u> , Cenatiempo, Y., Biochimie, 68, 1986, pps. 505-515.	
	*AT	<u>Bacterial Regulation: Global Regulatory Networks</u> , Gottesman, S., Ann. Rev. Genet., 18, 1984, pps. 415-441.	
	*AU	<u>Regulation <i>In Vivo</i> of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors</u> , Hamer, D.H. et al., Journal of Molecular and Applied Genetics, Vol. 1, No. 4, 1982, pps. 273-288.	
	*AV	<u>Functional Relationships between Transcriptional Control Signals of the Thymidine Kinase Gene of Herpes Simplex Virus</u> , McKnight, S.L., Cell, Vol. 31, 1982, pps. 355-365.	
	*AW	<u>Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon</u> , Johnston, S.A. et al., Proc. Natl. Acad. Sci. USA, 79, 1982, pps. 6971-6975.	
	*AX	<u><i>In vivo</i> sequence requirements of the SV40 early promoter region</u> , Benoist, C. et al., Nature, Vol. 290, 1981, pps. 304-310.	
	*AY	<u>Cloning, Structure, and Expression of the Mitochondrial Cytochrome P-450 Sterol 26-Hydroxylase, a Bile Acid Biosynthetic Enzyme</u> , Andersson, S. et al., The Journal of Biological Chemistry, Vol. 264, No. 14, 1989, pps. 8222-8229.	
	*AZ	<u>Insulin and Insulin-like Growth Factor Signaling Are Defective in the MDA MB-468 Human Breast Cancer Cell Line</u> , Sepp-Lorenzino, L. et al., Cell Growth & Differentiation, Vol. 5, 1994, pps. 1077-1083.	
	*BA	<u>Biochemical Analysis of the Epithelin Receptor</u> , Culouscou, J.M. et al., The Journal of Biological Chemistry, Vol. 268, No. 14, 1993, pps. 10458-10462.	
	*BB	<u>Targeted Toxins as Anticancer Agents</u> , Siegall, C.B., Cancer, Vol. 74, No. 3, 1994, pps. 1006-1012.	
✓	*CC	Zhang et al. <u>Proc. Natl. Acad. Sci. USA</u> . Vol. 95, pp. 14202-14207 (November 1998).	

Mark 7 7-7-03

Please type a plus sign (+) inside this box



PTO/SB/08B (08-00)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	April 4, 2001
				First Named Inventor	Ginette Serrero
				Group Art Unit	1642
				Examiner Name	M. Wells
Sheet	5	of	5	Attorney Docket Number	A7542.0000/P001-E

my	*DD	Crooke, S.T. in <u>Antisense Research and Application</u> (Stanley T. Crooke, Ed), Springer-Verlag, pp. 1-50, (July 1998).	
	*EE	Branch, A.D. <u>TIBS</u> , Vol. 23, pp. 45-50 (February 1998).	
	*FF	Gewirtz, A.M. et al. <u>Proc. Natl. Acad. Sci. USA</u> , Vol. 93, pp. 3161-3163 (April 1996).	
	*GG	Rojanasakul, Y. <u>Advanced Drug Delivery Reviews</u> , Vol. 18, pp. 115-131 (January 1996).	
	*HH	Anderson, W.F. <u>Nature</u> , Vol. 392, Suppl. pp. 25-30 (April 1998).	
	*II	Gura, T. <u>Science</u> , Vol. 278, pp. 1041-1042 (November 1997).	
	*JJ	Resnicoff, M. et al. <u>Cancer Res.</u> Vol. 54, pp. 2218-2222 (April 1994).	

Examiner Signature	<i>M. Wells</i>	Date Considered	7-7-03
--------------------	-----------------	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached



<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/824,647
				Filing Date	April 4, 2001
				First Named Inventor	Ginette Serrero
				Art Unit	1642
				Examiner Name	M. Yu
Sheet	1	of	1	Attorney Docket Number	A7542.0000/P001-E

RECEIVED

JUN 19 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
my	AA	6,309,826	10/30/2001	Serrero	
	AB	6,511,986	01/28/2003	Zhang, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		
my	CA	Runqing Lu, et al. - "Inhibition of PC cell-derived growth factor (PCDGF, epithelin/granulin precursor) expression by antisense PCDGF cDNA transfection inhibits tumorigenicity of the human breast carcinoma cell line MDA-MB-468," PNAS, Vol. 97, No. 8, April 11, 2000, pgs. 3993-3998.		
	CB	Vijay Bhandari, et al. - "Isolation and sequence of the granulin precursor cDNA from human bone marrow reveals tandem cysteine-rich granulin domains," Proc. Natl. Acad. Sci. USA, Vol. 89, March 1992, pgs. 1715-1719.		
	CC	Zhiheng He, et al. - "Progranulin Gene Expression Regulates Epithelial Cell Growth and Promotes Tumor Growth <i>in Vivo</i> ," Can Cer Research 59, July 1, 1999, pgs. 3222-3229.		
	CD	International Search Report dated May 13, 2003.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

my mood 7-7-03